Abatacept

Abatacept (marketed as Orencia) is a fusion protein composed of an immunoglobulin fused to the extracellular domain of CTLA-4, a molecule capable of binding B7. Abatacept is a selective costimulation modulator as it inhibits the costimulation of T cells. It was developed by Bristol-Myers-Squibb and is licensed in the United States for the treatment of rheumatoid arthritis in the case of inadequate response to anti-TNFα therapy.
See more at Wikipedia.org...

Abatacept Orencia Pharmacologic class: Selective costimulation modulator Therapeutic class: Antirheumatic Pregnancy risk category C Action Inhibits [more]Abatacept - Community and Resources